Chronic Respiratory Disease - the Acceptable Epidemic?
Overview
Authors
Affiliations
Chronic obstructive pulmonary disease (COPD) is a major cause of disability and death in the UK but is an even greater problem in low income countries. It is assumed by many to be almost entirely attributed to smoking. However, smoking alone cannot account for the distribution of the disease in the world and there is accumulating evidence that the disease is overwhelmingly a disease of poverty. The size of the problem and the failure of current hypotheses to explain the distribution of chronic lung disease make the lack of funding in this area surprising. The failure of science funders to respond to the analysis of the Cooksey report, which pointed out the extreme discrepancy between the size of the problem and the paucity of research funding, represents a serious failure in science policy. The lack of urgency in the face of such a large burden of illness suggests a degree of complacency in the face of a disease that is overwhelmingly a disease of the poor.
Williams P, Bachir L, Philip K, Cumella A, Polkey M, Laverty A BMJ Open. 2024; 14(4):e080282.
PMID: 38604645 PMC: 11015218. DOI: 10.1136/bmjopen-2023-080282.
Williams P, Buttery S, Laverty A, Hopkinson N Am J Respir Crit Care Med. 2024; 209(8):938-946.
PMID: 38300144 PMC: 11531224. DOI: 10.1164/rccm.202309-1650CI.
Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.
Chan Y, Singh S, Gulati M, Wadhwa S, Prasher P, Kumar D J Drug Deliv Sci Technol. 2022; 74:103541.
PMID: 35774068 PMC: 9221924. DOI: 10.1016/j.jddst.2022.103541.
Towards precision in defining COPD exacerbations.
Jenkins C Breathe (Sheff). 2022; 17(3):210081.
PMID: 35035551 PMC: 8753624. DOI: 10.1183/20734735.0081-2021.
The Impact of and Gene Polymorphisms in Pulmonary Diseases Including COVID-19.
Gintoni I, Adamopoulou M, Yapijakis C In Vivo. 2022; 36(1):13-29.
PMID: 34972696 PMC: 8765175. DOI: 10.21873/invivo.12672.